U.S. Nasal Spray Market, by Type (Prescription based(Branded, Generic), Over-The-Counter(Branded, Generic)), by Product Type ((Prescription based [Steroid Sprays{ Beclomethasone, Azelastine Hydrochloride And Fluticasone Propionate, Flunisolide, Mometasone Furoate , Fluticasone, Triamcinolone Acetonide , Budesonide, Others }],  [Antihistamine Sprays {Azelastine, Olopatadine Hydrochloride}], [Decongestant Sprays], [Others {Ipratropium Bromide, Naloxone, Others}]) (Over-the-Counter [Steroid Sprays {Fluticasone, Triamcinolone, Budesonide}] [Decongestant Sprays{Oxymetazoline, Phenylephrine, Xylometazoline}], [Saline Nasal Spray], Others)) by Indication (Allergic Rhinitis, Nasal Allergies, Nasal Congestion, Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), is estimated to be valued at US$  9,272.8 million in 2022, and is expected to exhibit a CAGR of 6.8% during the forecast period (2022-2030).

Increasing number of product launches by market players is expected to fuel the U.S. nasal spray market growth over the forecast period. For instance, in November 2021, Amcyte Pharma, a U.S.-based company committed to the development of cutting-edge pharmaceutical immunology products, announced the launch of its Nasitrol nasal spray for sinus irritation in the U.S.

Moreover, increasing number of awareness campaigns about allergies by non-profit organizations are expected to propel growth of the U.S. nasal spray market during the forecast period. For instance, The World Allergy Organization (WAO) held World Allergy Week from June 5 to 11, 2022, to promote awareness about how asthma and allergic airway illnesses are linked and how vital it is for both physicians and patients to understand and manage both.

U.S. Nasal Spray Market - Impact of Coronavirus (COVID – 19) Pandemic

The COVID-19 pandemic has affected the demand and supply of healthcare products in three main ways; by directly affecting the production and demand; by creating disruptions in distribution channels; and due to its financial impact on firms and financial markets. However, impact of the Coronavirus (COVID-19) pandemic is expected to aid in growth of the U.S. nasal spray market during the forecast period. For instance, on April 22, 2022, researchers at the Cornell University studied the use of antiviral nasal spray for the treatment of COVID-19 infection. The research is supported in part by the National Institute of Allergy and Infectious Diseases (NIAID). According to the study, the antiviral nasal spray has the potential to not only treat COVID-19 but also prevent SARS-CoV-2 infection in a way that the virus cannot mutate.

Browse12 Market Data Tables and 25 Figures spread through 179 Pages and in-depth TOC on US Nasal Spray Market by Type (Prescription based(Branded, Generic), Over-The-Counter(Branded, Generic)), by Product Type ((Prescription based [Steroid Sprays{ Beclomethasone, Azelastine Hydrochloride And Fluticasone Propionate, Flunisolide, Mometasone Furoate, Fluticasone, Triamcinolone Acetonide , Budesonide, Others }],  [Antihistamine Sprays {Azelastine, Olopatadine Hydrochloride}], [Decongestant Sprays], [Others {Ipratropium Bromide, Naloxone, Others}]) (Over-the-Counter [Steroid Sprays {Fluticasone, Triamcinolone, Budesonide}] [Decongestant Sprays{Oxymetazoline, Phenylephrine, Xylometazoline}], [Saline Nasal Spray], Others)) by Indication (Allergic Rhinitis, Nasal Allergies, Nasal Congestion, Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies).

To know the latest trends and insights prevalent in the U.S. Nasal Spray Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/us-nasal-spray-market-5261

Key Takeaways of the US Nasal Spray Market:

  • U.S. nasal spray market is expected to exhibit a CAGR of 6.8% over the forecast period (2022-2030), owing to the increasing number of product approvals by market players, which is expected to fuel the U.S. nasal spray market growth over the forecast period. For instance, in March 2022, Perrigo Company Plc, a provider of self-care products and over-the-counter (OTC) health and wellness solutions, announced that it had received final approval form the U.S Food and Drug Administration for the over-the-counter use of Nasonex 24HR Allergery (Mometasone furoate monohydrate 50 mcg).
  • Some of the major players operating in the U.S. nasal spray market include GlaxoSmithKline plc, Sanofi S.A., Bayer AG, Merck & Co., Inc., Novartis AG, Johnson & Johnson Services, Inc., Pfizer Inc., Procter & Gamble, AstraZeneca Plc., NeilMed Pharmaceuticals Inc., Church & Dwight Co., Inc., and Neurelis, Inc.

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo